Associated tags: Lymph, Amphiphile, Vaccine, Infection, Engineering, Therapy, Cancer, Immunotherapy, Amplifier, Pharmaceutical industry, AMP, Patient, KRAS, Research, Elicio Berriz, Neoplasm, Development, Immune system
Locations: CAMBRIDGE, NEW YORK, KRAS, CA, SAN FRANCISCO, LOS ANGELES, CALIFORNIA, MA, US, UNITED STATES
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held May 31-June 4, 2024 in Chicago, IL.
Key Points:
- BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held May 31-June 4, 2024 in Chicago, IL.
- The AMPLIFY-7P study is evaluating the 7-peptide formulation of Elicio’s off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors that are positive for minimal residual disease.
- ELI-002 7P is designed to stimulate an immune response against the seven KRAS mutations that drive 25% of all solid tumors.
- Presenter: Craig E. Devoe, M.D., MHCM., Chief, Division of Medical Oncology & Hematology, R.J Zuckerberg Cancer Center, and Scientific Investigator, Northwell Health
CD4,
CD8,
AMP,
Development,
Antigen,
Immunotherapy,
Colorectal cancer,
Memory,
Patient,
Lung,
GM-CSF,
Biomarker,
DNA,
Epitope,
Cancer,
Granzyme B,
BRAF,
Lymph,
IL2,
Circulating tumor DNA,
Phenotype,
Neoplasm,
Research and development,
Immunization,
Therapy,
Vaccination,
CRC,
V600E,
Immune system,
Melanoma,
Granzyme,
Phase 1,
Amphetamine,
Nature Medicine,
Annual general meeting,
Vaccine Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
Key Points:
- Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
- A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
- The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
- "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.
BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.
Key Points:
- BOSTON, March 29, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.
- The independent data monitoring committee completed the safety review of ELI-002 7P Phase 1 trial patients and confirmed the recommended Phase 2 trial dose.
- No safety concerns were identified, and no dose limiting toxicities and no ≥ grade 3 treatment related adverse events were observed.
- Cash and cash equivalents as of December 31, 2023, were $12.9 million, compared to $6.2 million as of December 31, 2022.
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant in a private placement to GKCC, LLC.
Key Points:
- BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant in a private placement to GKCC, LLC.
- Gross proceeds of the private placement are expected to be approximately $6.0 million, before deducting expenses.
- The private placement is expected to close on March 19, 2024, subject to the satisfaction of customary closing conditions.
- Elicio intends to use the net proceeds for the advancement of its development pipeline, as well as for working capital and general corporate purposes.
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.
Key Points:
- BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.
- The presentations will highlight data on Elicio’s therapeutic cancer vaccine candidates, ELI-002, ELI-007 and ELI-008, built using Elicio’s Amphiphile (“AMP”) technology, which harnesses the power of the lymph nodes to generate and activate T cells to target solid tumors.
- Presentation Title: Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer
Presentation Title: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity
Presentation Title: AMP-peptide vaccination against mutant BRAF epitopes promotes lymph node delivery to generate potent, functional T cell immunity
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
Key Points:
- BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
- A live webcast of the presentation will be accessible under “ Events ” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
Retrieved on:
Thursday, January 25, 2024
Tumor microenvironment,
Death,
Patient,
Therapy,
Neoplasm,
AMP,
Cancer,
E7,
Peptide,
Immunotherapy,
Risk,
Recurrence,
Lymph,
Cancer Immunology Research,
Doctor of Philosophy,
NY-ESO-1,
Research,
Vaccine These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.
Key Points:
- These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies (“TCR-T cells”) enhancing anti-tumor function and eradicating solid tumors.
- “Optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics.
- “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication.
- AMP immunotherapy led to enhanced lymph node delivery and correlated with pro-inflammatory lymph node transcriptional reprogramming and increased antigen-presenting cell maturation, resulting in TCR-T cell expansion and functional enhancement.
Retrieved on:
Wednesday, January 17, 2024
Tumor microenvironment,
Development,
Death,
Pancreatic cancer,
Patient,
Therapy,
Cancer,
Neoplasm,
DNA,
Pancreas,
Standard of care,
Survival,
AMP,
Poster,
University,
Lymphocyte,
Risk,
HLA,
Safety,
UCLA,
Lymph,
CA19-9,
Immunization,
University of California,
PDAC,
Research and development,
Observation,
Biopsy,
Colorectal cancer,
Nature Medicine,
RAS,
Pharmaceutical industry The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
Key Points:
- The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
- “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
- AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
- A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.
Retrieved on:
Tuesday, January 16, 2024
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.
Key Points:
- BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.
- To access this event, please RSVP to your B. Riley Securities sales representative.
- A replay of Elicio’s fireside chat will be accessible under “ Events ” in the Investors section of Elicio’s website, www.elicio.com , after the meeting.
Retrieved on:
Thursday, January 11, 2024
Development,
Pancreatic cancer,
Death,
Patient,
Therapy,
Cancer,
Neoplasm,
Risk,
PDAC,
Research and development,
Medical research,
Biomarker,
Nature Medicine,
Pharmaceutical industry This is in contrast to other KRAS-targeted therapeutics in development — particularly small molecule KRAS inhibitors — which target fewer mutations, potentially limiting the number of patients that can be treated and also limiting duration of benefit due to development of escape mutants.
Key Points:
- This is in contrast to other KRAS-targeted therapeutics in development — particularly small molecule KRAS inhibitors — which target fewer mutations, potentially limiting the number of patients that can be treated and also limiting duration of benefit due to development of escape mutants.
- “ELI-002 represents a cancer vaccine approach that could potentially address the much broader spectrum of pancreatic cancer KRAS mutations.
- The Phase 2 study builds on positive findings from our 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating a significantly improved decrease in tumor biomarkers, along with strong T cell responses that correlated with a reduced risk of relapse and death.
- Initial interim data on ELI-002 7P monotherapy from Phase 1A arm will be shared in the first half of 2024.
